| 臺大學術典藏 |
2022-02-23T02:12:26Z |
Consensus development from the 5th asia-pacific primary liver cancer expert meeting (APPLE 2014)
|
Hsu C.; Chen B.-B.; CHIEN-HUNG CHEN; Ho M.-C.; Cheng J.C.-H.; Kokudo N.; Murakami T.; Yeo W.; Seong J.; Jia J.-D.; Han K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-02-23T02:12:26Z |
Up-regulation of MicroRNA-190b plays a role for decreased IGF-1 that induces insulin resistance in human hepatocellular carcinoma
|
Hung T.-M.; Ho C.-M.; Liu Y.-C.; Lee J.-L.; Liao Y.-R.; Wu Y.-M.; Ho M.-C.; CHIEN-HUNG CHEN; Lai H.-S.; Lee P.-H. |
| 臺大學術典藏 |
2022-02-23T02:12:24Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; CHIEN-HUNG CHEN; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2022-02-23T02:12:20Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; CHIEN-HUNG CHEN; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2022-02-22T05:34:27Z |
Clinical manifestations and survival of hepatocellular carcinoma patients with peritoneal metastasis
|
Lin C.-C.; Liang H.-P.; Lee H.-S.; Huang G.-T.; Yang P.-M.; Ho M.-C.; Lee P.-H.; Tsang Y.-M.; Chen D.-S.; Sheu J.-C.; CHIEN-HUNG CHEN |
| 臺大學術典藏 |
2022-02-22T05:34:27Z |
Liver resection improves the survival of patients with multiple hepatocellular carcinomas
|
Ho M.-C.; Huang G.-T.; Tsang Y.-M.; Lee P.-H.; Chen D.-S.; Sheu J.-C.; CHIEN-HUNG CHEN |
| 臺大學術典藏 |
2022-02-22T05:34:18Z |
Elevated preoperative serum ca19-9 levels in patients with hepatocellular carcinoma is associated with poor prognosis after resection
|
Chen Y.-L.; CHIEN-HUNG CHEN; Hu R.-H.; Ho M.-C.; Jeng Y.-M. |
| 臺大學術典藏 |
2022-02-22T05:34:17Z |
Up-regulation of MicroRNA-190b plays a role for decreased IGF-1 that induces insulin resistance in human hepatocellular carcinoma
|
Hung T.-M.; Ho C.-M.; Liu Y.-C.; Lee J.-L.; Liao Y.-R.; Wu Y.-M.; Ho M.-C.; CHIEN-HUNG CHEN; Lai H.-S.; Lee P.-H. |
| 臺大學術典藏 |
2022-02-22T05:34:16Z |
Consensus development from the 5th asia-pacific primary liver cancer expert meeting (APPLE 2014)
|
Hsu C.; Chen B.-B.; CHIEN-HUNG CHEN; Ho M.-C.; Cheng J.C.-H.; Kokudo N.; Murakami T.; Yeo W.; Seong J.; Jia J.-D.; Han K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-02-22T05:34:15Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; CHIEN-HUNG CHEN; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2022-02-22T05:34:10Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; CHIEN-HUNG CHEN; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2022-02-16T03:00:55Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao, Yu-Yun; Wang, Shen-Yung; Lin, Shi-Ming; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; JA-DER LIANG |
| 臺大學術典藏 |
2022-02-14T07:10:52Z |
Metabolic risk factors are associated with non-hepatitis B non-hepatitis C hepatocellular carcinoma in Taiwan, an endemic area of chronic hepatitis B
|
Huang S.-F.; Chang I.-C.; Hong C.-C.; Yen T.-C.; Chen C.-L.; Wu C.-C.; Tsai C.-C.; Ho M.-C.; Lee W.-C.; Yu H.-C.; Shen Y.-Y.; Eng H.-L.; Wang J.; Tseng H.-H.; YUNG-MING JENG; Yeh C.-T.; Chen C.-L.; Chen P.-J.; Liaw Y.-F. |
| 臺大學術典藏 |
2022-02-07T03:29:02Z |
Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance
|
Wang Y.; Lu L.-C.; Guan Y.; Ho M.-C.; Lu S.; Spahn J.; CHIH-HUNG HSU |
| 臺大學術典藏 |
2022-01-25T05:07:25Z |
Long-term outcomes after resection versus transplantation for hepatocellular carcinoma within UCSF criteria
|
Ho C.-M.; Lee P.-H.; CHI-LING CHEN; Ho M.-C.; Wu Y.-M.; Hu R.-H. |
| 臺大學術典藏 |
2022-01-25T03:25:06Z |
Metabolic risk factors are associated with non-hepatitis B non-hepatitis C hepatocellular carcinoma in Taiwan, an endemic area of chronic hepatitis B
|
Huang S.-F.; Chang I.-C.; Hong C.-C.; Yen T.-C.; CHI-LING CHEN; Wu C.-C.; Tsai C.-C.; Ho M.-C.; Lee W.-C.; Yu H.-C.; Shen Y.-Y.; Eng H.-L.; Wang J.; Tseng H.-H.; Jeng Y.-M.; Yeh C.-T.; Chen C.-L.; Chen P.-J.; Liaw Y.-F. |
| 臺大學術典藏 |
2022-01-25T03:24:59Z |
Dynamic prognostication in transplant candidates with acute-on-chronic liver failure
|
Lu C.-Y.; CHI-LING CHEN; Ho C.-M.; Hsiao C.-Y.; Wu Y.-M.; Ho M.-C.; Lee P.-H.; Hu R.-H. |
| 臺大學術典藏 |
2022-01-25T03:24:59Z |
Cell-Free Virus-Host Chimera DNA From Hepatitis B Virus Integration Sites as a Circulating Biomarker of Hepatocellular Cancer
|
Li C.-L.; Ho M.-C.; Lin Y.-Y.; Tzeng S.-T.; Chen Y.-J.; Pai H.-Y.; Wang Y.-C.; CHI-LING CHEN; Lee Y.-H.; Chen D.-S.; Yeh S.-H.; Chen P.-J. |
| 臺大學術典藏 |
2022-01-24T09:32:03Z |
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
|
CHUN-JEN LIU; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Lee C.-C.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. |
| 臺大學術典藏 |
2022-01-24T09:31:38Z |
Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence
|
CHUN-JEN LIU; Chang J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin Y.-J.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Yang M.-D.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. |
| 臺大學術典藏 |
2022-01-24T09:31:15Z |
Expression of Metastatic Tumor Antigen 1 Splice Variant Correlates With Early Recurrence and Aggressive Features of Hepatitis B Virus–Associated Hepatocellular Carcinoma
|
Li Y.-T.; Wu H.-L.; Kao J.-H.; Cheng H.-R.; Ho M.-C.; Wang C.-C.; Chen P.-J.; Chen D.-S.; CHUN-JEN LIU |
| 臺大學術典藏 |
2022-01-24T09:30:58Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; CHUN-JEN LIU; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2022-01-24T06:05:35Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; CHIUN HSU; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2021-09-15T01:20:49Z |
Reliability of a single-region sample to evaluate tumor immune microenvironment in hepatocellular carcinoma
|
Shen Y.-C.; CHIA-LANG HSU; Jeng Y.-M.; Ho M.-C.; Ho C.-M.; Yeh C.-P.; Yeh C.-Y.; Hsu M.-C.; Hu R.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-09-04T05:16:50Z |
Expression of Metastatic Tumor Antigen 1 Splice Variant Correlates With Early Recurrence and Aggressive Features of Hepatitis B Virus–Associated Hepatocellular Carcinoma
|
Li Y.-T.; Wu H.-L.; JIA-HORNG KAO; Cheng H.-R.; Ho M.-C.; Wang C.-C.; Chen P.-J.; Chen D.-S.; Liu C.-J. |
